Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer

Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Nat Commun
Главные авторы: He, Yundong, Peng, Shihong, Wang, Jinhua, Chen, Huang, Cong, Xiaonan, Chen, Ang, Hu, Meichun, Qin, Min, Wu, Haigang, Gao, Shuman, Wang, Liguo, Wang, Xin, Yi, Zhengfang, Liu, Mingyao
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5159881/
https://ncbi.nlm.nih.gov/pubmed/27959342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms13122
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы